Date: 2016-03-04
Type of information: discontinuation of development
phase: 1-2
Announcement: dosing of the first patient
Company: Akinion Pharmaceuticals (Sweden)
Product: AKN-028
Action
mechanism: AKN-028 is a targeted oral small molecule FLT3 and cKIT kinase inhibitor with a unique differentiating efficacy against leukemic cells resistant to current therapies.
Disease: acute myeloid leukemia (AML)
Therapeutic area: Cancer - Oncology
Country:
Trial
details: The Phase I/II trial with AKN-028 is a two-part international multi-center study in patients with AML. The first part is a dose-escalating study where AKN-028 is administered orally twice a day, until the maximum tolerated dose is established. The second part is a proof-of-concept study where approximately 20 patients will be treated.
The trial will assess the safety, tolerability, pharmacokinetics and anti-leukemic effect of AKN-028.
Latest
news: * On March 4, 2016 , Akinion Pharmaceuticals AB today announces that it has halted further development of its lead product candidate AKN-028, which was being evaluated in a Phase I/II clinical study for acute myeloid leukemia (AML), due to a small number of patients experiencing severe liver toxicity. * On January 9, 2012, Akinion Pharmaceuticals AB, a Karolinska Development AB portfolio company, has announced that the first patient has been dosed with AKN-028 in a Phase I/II clinical trial in acute myeloid leukemia (AML).
